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Abstract Initiation of translation in hepatitis C virus (HCV) is
dependent on the presence of an internal ribosome entry site
(IRES) contained in its 341-nt-long 5P-untranslated region
(UTR). This region is very conserved among different isolates
and has been used to classify HCV isolates in six different
genotypes. These genotypes differ in nucleotide sequence that
generally preserve the IRES structure. However, the small
differences seen may be biologically and clinically significant as
the HCV strains seem to differ from each other in several
important ways, such as the behaviour of the viral infection and
the response to interferon therapy. Therefore, differences in
translational initiation efficiency amongst the various genotypes
could provide an explanation for these phenomena. Using a
bicistronic expression system we have compared the in vivo
translational ability of the three most common European
genotypes of HCV (1, 2, and 3). The results show that
genotype 3 is less able than 1 and 2 to promote translation
initiation. In addition, by site-directed mutagenesis of the
sequence of the IRES domain III apical stem loop structure,
we have shown that the conservation of the primary nucleotide
sequence and not only the structure, is important for the
conservation of IRES function.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
The sequence of the 5P-UTR region of hepatitis C virus [1,2]
is highly conserved among di¡erent isolates [3] and has been
used to classify the existing viral strains in six distinct virus
genotypes [4]. Structural studies have shown that it forms a
complex secondary structure resembling closely that of the
recently isolated GB virus B (GBV-B) [5,6]. Initial studies
performed on HCV 5P-UTRs con¢rmed that it contains an
IRES, a structure capable of driving cap-independent transla-
tional initiation [7,8]. Several key elements important for its
function have been identi¢ed as belonging to conserved stem-
loop structures [6], a double-stranded region [9] and also a
pseudoknot structure [10]. One of the stem-loop elements
known as domain III, represents the largest secondary struc-
ture with multiple stem loops contained in the HCV IRES [6].
This domain contains several potentially important features
for the regulation of translation: a pyrimidine-rich tract (nt
191^199) followed by an AUG triplet located about 20 nu-
cleotides downstream [11], similar to those already observed
in Picornavirus IRES elements [12,13], and a region (nt 192^
203) complementary to bases 461^471 of human 18S RNA [5].
Deletion of this domain causes the complete loss of IRES
functioning [9]. In addition, several deletion analyses were
performed to map the minimal IRES sequences [7^10,14^
16]. The 5P-end of HCV UTR is generally considered to be
positioned at nucleotide 45 but the 3P-boundary has been the
subject of some controversy. In fact, unlike what was known
for picornavirus IRESs, it was found that HCV IRES also
seemed to extend several nucleotides (W30) in the coding
region of the HCV core protein [17]. However, most of the
earlier studies performed on HCV IRESs had used monocis-
tronic and bicistronic expression systems which did not con-
tain any HCV core protein sequence and yet displayed a good
level of internal translation initiation. The reason for this
apparent discrepancy has been addressed in a recent work
[6] which provides an explanation for the involvement of the
core coding region, and showed that the stability of a con-
served stem-loop which is present there (domain IV) is in-
versely correlated with e¤ciency of translation initiation. It
has been suggested that the usefulness for HCV of possessing
such an inhibitory structure would be to contribute in the in
vivo regulation of viral translation mediated through a bind-
ing with regulatory proteins, either of viral or cellular origin
[6]. The existence of such complex regulatory pathways means
that any study comparing the translational ability of di¡erent
5P-UTRs of HCV should be carried out in in vivo assays. In
fact, it has been shown that the HCV IRES function is more
e¤cient in vivo than in vitro [18].
In the present study we have measured the e¤ciency of
translation of di¡erent 5P-UTR representative sequences be-
longing to genotypes 1, 2, and 3. Full-length and truncated 5P-
UTR sequences were inserted in a bicistronic expression vec-
tor and transfected in COS-1 cells. The results of this analysis
suggest that the 5P-UTR of genotype 3 is the IRES least able
to promote translation initiation, whilst 1 and 2 had compar-
able e¤ciencies. In addition we have also studied three arti¢-
cial mutants of the domain III of genotype 3. The results of
this second study demonstrate that not only the maintenance
of domain III secondary structure plays an essential role in
IRES functioning but also the primary sequence of the stem is
important for translation initiation.
2. Materials and methods
2.1. HCV 5P-UTR sequences employed in this study
HCV 5P-UTR sequences spanning from nucleotide 46 to 341 of the
di¡erent genotypes were ampli¢ed from patients sera [19] and classi-
¢ed accordingly [20]. The ampli¢ed products were then cloned in the
KpnI/HindIII pBlueScript SK+ plasmids (Stratagene, La Jolla, CA).
The sequence belonging to genotype 1 (UTR-1) had a 100% identity
with the already published HCV-1b sequence [21], the sequence for
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genotype 2 (UTR-2) with HCV-2a [22] and the one for genotype 3
with Eb 1 [20].
5P-UTR mutated sequences based on the 5P-UTR of genotype 3 as
a template were generated by PCR using pairs of complementary
oligonucleotides containing the desired mutation. Three arti¢cial mu-
tants were generated: in the ¢rst one (UTR-3/195), the polypyrimidine
stretch at the top of domain III was mutated to a stretch of polypur-
ines. In the second one (UTR-3/207), the stem-loop structure under-
neath domain III was disrupted whilst in the third (UTR-3/188/207),
compensatory mutations were introduced to restore base pairing. This
double-mutation was obtained using UTR-3/207 as a template. To
generate these arti¢cial mutants we used the following pairs of pri-
mers: UTR-3/195 (K297S/LOOP-AS; LOOP-S/HAS1), for UTR-3/
207 (K297S/STDIS-AS; STDIS-S/HAS1), for UTR-3/188/207
(K297S/STASC-AS; STASC-S/HAS1). The sequence of the above
mentioned primers are as follows: 5P-TTGGTACCTGTGAGGAAC-
TACTGTCT-3P (K297S); 5P-TTGATCCCCCCCCGGACCCG-3P
(LOOP-AS); 5P-CGGGTCCGGGGGGGGATCAA-3P (LOOP-S);
5P-TTAAGCTTGGTGCACGGTCTACGAGACCT-3P (HAS1); 5P-
GTATTGAGGCCCATGTTCCA-3P (STDIS-AS); 5P-TGGAACAT-
GGGCCTAATAC-3P (STDIS-S); 5P-AGAAAGGTGGGCGTCAC-
CC-3P (STASC-AS); and 5P-GGGTGACGCCCACCTTTCT-3P
(STASC-S).
2.2. pSV GH/CAT expression vectors construction
The di¡erent 5P-UTRs were inserted in the pSV GH-CAT bicis-
tronic expression system [23]. The polylinker of this plasmid was
modi¢ed to insert a KpnI and XbaI restriction site and to bring the
HindIII restriction enzyme site adjacent to the ATG nucleotides of the
CAT reporter gene. This was performed by amplifying the polylinker
and part of the CAT coding sequence using primers: 5P-CTTAAG-
GATATCGGTACCTCTAGAAAGCTTATGGAGAAAAAAAT-
CACTGG-3P and 5P-CGGAATTCCGGATGAGCATTC-3P and in-
serting back the ampli¢ed product using the EcoRV and BspEI
unique restriction sites. Therefore, the six di¡erent 5P-UTRs spanning
from nucleotide 45 to 341 were inserted in this position: UTR-1 (pSV
UTR-1), UTR-2 (pSV UTR-2), UTR-3 (pSV UTR-3), UTR-3/195
(pSV UTR-3/195), UTR-3/207 (pSV UTR-3/207), and UTR-3/188/
207 (pSV UTR-3/188/207). A schematic representation of these con-
structs is shown in Fig. 1A. In a second set of experiments the HCV-
BK core protein [24] was ampli¢ed by PCR together with genotypes 1,
2, and 3 5P-UTRs in such a way as not to leave any nucleotide
between the end of the 5P-UTR and the ¢rst codon of the core pro-
tein. This approach also gave us the possibility to insert the ¢rst 45
nucleotides of each UTR. In brief, domain I was inserted by amplify-
ing from the pSV GH/CAT plasmids described using a 5P-primer (P1)
containing the sequence 5P-GCCGCCCCCTGATGGGGGCGA-
CACTCCACCATGAATCACTCCCCTGTGAGGAACT-3P and a
3P-primer (P2) containing the ¢rst four residues of the BK core pro-
tein: 5P-ATTCGTGCTCATGGTGCACGGTCTACGA-3P. A second
PCR was then performed using as a 5P-primer (P3) its complementary
sequence: 5P-TCGTAGACCGTGCACCATGAGCACGAAT-3P and
a 3P-primer (P4) which contained the end of the HSV Tag hinge
region in frame with the last three codons of the HCV BK core
protein: 5P-TCCGCCAGATGCAGCGGAAGCT-3P. A third PCR
was performed to amplify a GSGGG hinge region together with a
13 amino acid HSV-Tag using as 5P-primer (P5): 5P-
GGATCTGGCGGAGGTCAGCCTGAACTCGCTCCAG-3P and as
a 3P-primer (P6) containing an HindIII restriction enzyme site: 5P-
TATTAAGCTTTTATCACTAATCTTCCGGATC-3P. The ampli¢ed
products of P3/P4 and P5/P6 were denatured together and ampli¢ed
with P3 and P6. The product was an HCV core protein containing a
13 amino acid HSV Tag terminal sequence (QPELAPEDPED) from
the herpes simplex virus glycoprotein D joined to the protein with a
GSGGG hinge. This product was then denatured together with the
P1/P2 ampli¢ed product. A last round of ampli¢cation was performed
using a 5P-primer which contained an XbaI cloning site and a T7
promoter (which was inserted as a spacer region from the end of
the hGH gene): 5P-AAATCTCTAGATAATACGACTCAC-
TAGTGGGTACCGCCAGCCCCCTG-3P and as a 3P-primer P6.
The ampli¢ed product was then inserted in the XbaI and HindIII
cloning sites in the pSV GH-CAT plasmid and sequenced. Therefore,
a second set of plasmids (pSV UTR-1core, pSV UTR-2core, pSV
UTR-3core) was then prepared which contained the three di¡erent
5P-UTRs fused with the BK-core protein (now becoming the second
cistron). A schematic representation of these constructs is shown in
Fig. 1B. The HSV-Tag region gave us the possibility to recognize the
core protein with a commercially available mouse monoclonal anti-
body (HSV Tag Antibody, Novagen).
2.3. Transfection of COS-1 cells with the pSV GH/CAT expression
systems
The eight 5P-UTRs inserted into the pSV GH/CAT expression vec-
tor were used to transfect COS-1 cells using DOTAP (Boehringer
Mannheim) according to manufacturer's protocol. Cells (400 000)
were seeded in 60 mm dishes and after 24 h they were transfected
with 4 Wg of each plasmid in a serum-free medium. After 4 h the
serum-free medium was replaced with complete medium. Cells were
then harvested after 48 h and the human growth hormone (hGH)
levels in the cell medium were quanti¢ed by a radio-immuno assay
kit (Nichols Institute Diagnostics, San Juan Capistrano, CA). The
hGH levels were then used to normalize the amount of cellular lysate
used for CAT assays and Western blot procedures. The CAT levels
obtained for each construct were performed according to standard
protocols [25] and quanti¢ed using a phosphoimager (Packard, In-
stantImager). The relative amounts of core protein produced were
recognized by mAb B12.F8 [26] and quantitized using a Bio-Rad
GS-670 Densitometer. The Bio-Rad Molecular Analyst computer pro-
gramme was used to integrate the intensity of the di¡erent bands.
Cellular extracts used for CAT activity and HCV core protein pro-
duction were normalized to the level of GH activity. The values in the
graphs of Figs. 2 and 3 represent averages from at least three inde-
pendent experiments with a variation among the di¡erent experiments
of less than 20%. IRES e¤ciency of the various genotypes is expressed
as a percentage of the total IRES activities in the di¡erent experi-
ments.
3. Results
The in vivo translational e¤ciency of HCV 5P-UTRs be-
longing to di¡erent genotypes of the virus was investigated
by transfection assays in COS-1 cells. All UTRs were inserted
in the second cistron of the bicistronic expression vector pSV
GH-CAT [23] which allowed an accurate standardization of
the transfection assays by measuring the amount of hGH
released in the culture media. A ¢rst set of experiments was
performed with the CAT enzyme reporter gene under the con-
trol of the di¡erent UTRs. The results of these transfections
show that, whilst genotype 1 and 2 have similar translation
e¤ciencies, genotype 3 is about 40% less e¡ective (Fig. 2A).
These experiments suggested a signi¢cant di¡erence, but were
not de¢nitive as these pSV constructs (Fig. 1A) did not con-
tain the entire HCV 5P-UTR. In fact, they lacked both the
¢rst 45 nucleotides (domain I) and the initial core coding re-
gion (which contributes to domain IV). Therefore, a new set
of constructs (Fig. 1B) was designed to add domain IV by
including the HCV-BK core protein [24]. These constructs
also included the ¢rst 45 nucleotides of the 5P-UTR which,
although not considered to be essential for IRES functioning
[14], could be involved in the in vivo regulation of translation.
The amount of core protein produced by each UTR was
measured by Western blot procedure using a monoclonal anti-
body B12.F8 [26] speci¢c for aa 34^45 of the core protein. The
results (Fig. 2B) are even more evident than that observed in
Fig. 2A, with genotype 3 being 50% less able to promote
translation initiation than genotypes 1 and 2. In addition, as
the levels of growth hormone produced by equal amounts of
plasmids in the di¡erent transfections never varied by more
than 20%, a clear indication was provided that the stability of
the di¡erent transcripts in the transfected cells were compara-
ble.
When the mAb B12.F8 was used to detect the expression of
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Fig. 1. Schematic representation of the pSV GH-CAT plasmids used for this work. A: The bicistronic portion of the plasmids in which the dif-
ferent 5P-UTRs controlled the expression of the CAT reporter gene. B: Diagram of the constructs where the complete 5P-UTRs were fused to
the HCV core protein (containing the C-terminal HSV Tag sequence). This allowed the inclusion of domains I and IV, as shown in the draw-
ing above the 5P-UTR box. C: Predicted secondary structures of the di¡erent domain III sequences of the HCV 5P-UTRs. The nucleotides dif-
ferences between the di¡erent genotypes are shown in bold letters and marked with an point. UTR1, genotype 1a; UTR2, genotype 2b;
UTR3, genotype 3.
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the core protein it recognized two distinct bands of 21 and 25
kDa respectively (Fig. 2B). These bands are due to the already
described C-terminal proteolytic cleavage of the HCV-BK
core protein [27]. Using an anti-HSV Tag speci¢c mAb we
have con¢rmed that this processing occurs at the C-terminal
end of the HCV core protein (data not shown). The di¡erence
in molecular weight between the processed and unprocessed
core protein in our experiments (21 and 25 kDa) is greater
than what had been previously described (21 and 23 kDa) due
to the addition in our constructs of the HSV Tag sequence
(Buratti et al., unpublished results).
As genotype 3 is the least studied of the European most
common genotypes we decided to perform, in parallel, some
arti¢cial mutations of its domain III. We have mutated the
poly-pyrimidine tract (nt 195^200) from UUUCUU to
GGGGGG (pSV UTR-3/195). In another mutant, pSV
UTR-3/207, the descending arm (ACCCG) of the apical
stem (nt 207^211) was mutated to UGGGC, whilst a stem-
restoring compensatory mutation was then engineered in pSV
UTR-3/188/207. The experiments show that both the pSV
UTR-3/195 (Fig. 3A) and pSV UTR-3/207 (Fig. 3B) muta-
tions greatly reduced translation e¤ciency. Interestingly, the
UTR containing the compensatory mutation (UTR-3/188/207)
recovers only 60% of the original translational initiation abil-
ity (Fig. 3B).
4. Discussion
The aim of this study was to compare the translational
initiation ability of representative HCV 5P-UTR sequences
belonging to di¡erent HCV genotypes (1, 2, and 3). Using a
bicistronic expression vector we have shown that the UTR of
genotype 3 is approximately 50% less able to promote trans-
lation initiation than the UTRs of genotype 1 and 2. In addi-
tion, our experiments provide consistent evidence that HCV
genotype 1 and 2 show similar e¤ciencies. The only previous
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Fig. 2. A: Representative CAT assay using pSV UTR-1 (1), pSV UTR-2 (2), and pSV UTR-3 (3). The amount of cellular extract used in each
experiment was normalized using the amount of growth hormone released in the culture media. Relative CAT intensities were measured using
a Phosphoimager and the graph on the right represents the mean results of three independent experiments. B: Western blot of COS-1 cells (to-
tal cellular extract) transfected with plasmids: pSV UTR-1core (1), pSV UTR-2core (2) and pSV UTR-3core (3). Both the 25 kDa and 21 kDa
forms (marked with an arrow) of the core protein were recognized by the core-speci¢c mAb B12.F8. Band intensities were measured using a
Bio-Rad Densitometer. The graph on the right shows the results (+SD) of three independent experiments.
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comparative study on the e¤ciency of di¡erent genotypes
suggested that the IRES of genotype 2 was more e¤cient
than that of genotype 1 [7]. However, it must be considered
that these authors used a cell-free protein synthesis system and
that, conditions were quite di¡erent from those employed
by us.
The use of the BK core protein in all the constructs implied
that the sequence of position 9^11 in the core region was
GAA (typical of genotype 1 and 2) and not ACT (character-
istic of genotype 3) [3]. These nucleotide changes are the same
(and in the same position) as those observed for the TH33
strain of HCV [28], whose possible domain IV structure had
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Fig. 3. CAT expression in COS-1 cells after transfection with the di¡erent pSV UTR-3 plasmids bearing arti¢cial mutations in the apical stem
and apical loop of domain III. A: pSV UTR-3 (3) and pSV UTR-3/195 (4). B: pSV UTR-3 (3), pSV UTR-3/207 (5), and pSV UTR-3/188/207
(6). The inset diagrams show a graphic representation of the di¡erent mutations introduced. Relative CAT intensities were measured using a
Phosphoimager and the graph on the right represents the mean results of three independent experiments.
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already been calculated, and which was predicted to mini-
mally alter the structure of the stem-loop [6].
With the use of arti¢cial mutants, we have also focused our
attention on the stem-loop structure known as domain III,
not only because this is where most nucleotide di¡erences
between genotypes occur, but also because this region may
be the target for several protein^RNA interactions [29,30].
Previous mutational analysis of this loop [9] showed that
the substitution of three nucleotides in the 195^200 polypyr-
imidine tract had no e¡ect on IRES translational capabilities.
Its total deletion completely abolished IRES functioning [9]
and this leads to the impression that structural alterations in
the apical part of domain III were tolerable. We feel that our
mutation analysis in the same region should partially modify
this view. In fact, the six-base substitution engineered in mu-
tant UTR-3/195 almost completely abolished translation ini-
tiation. Although we cannot rule out that the presence of six
Gs could lead to the acquisition of a radically di¡erent struc-
ture from the proposed models [10] it is possible that, unlike
the one previously performed [9], this mutation might be suf-
¢ciently severe in order to interfere with the binding of pro-
teins such as PTB [29] or with the suggested complementarity
to the human 18S ribosomal sub-unit [5].
Interestingly, whilst base-pair disruption in the stem organ-
ization (mutant UTR-3/207) leads to a high reduction of
translation initiation, the corresponding compensation in the
mutant UTR-3/188/207 only partially recovered the loss. This
partial recovery of activity highlights the importance of main-
taining not only the secondary structure but also the primary
sequence of the stem.
Our results show unequivocally that HCV 5P-UTR belong-
ing to di¡erent genotypes can have di¡erent translational ini-
tiation capabilities. Interestingly, several studies have demon-
strated that the HCV genotype of the infecting virus
in£uences the response to IFN-K. In fact, patients infected
with genotype 3 usually respond better in comparison with
the other infecting genotypes [31]. The mechanism of action
of IFN is not clear. A component in translation regulation
controls sensitive to IFN and di¡erences between geno-
types 1^2 and genotype 3 are an interesting possibility to
study. In addition, the changes in translational ability which
we observed as a consequence of mutating key regions of the
UTR lend more credibility to the emerging view that HCV
translation might be dependent on the interaction with either
cellular or viral factors. Further work on the nature of these
interactions may lead to a better understanding of several
characteristics of the di¡erent HCV infecting genotypes.
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